Abstract
Carbidopa/levodopa enteral suspension [carbidopa/levodopa ES; Duopa™ (USA); Duodopa® (EU, where it is referred to as intestinal gel)] is indicated for the treatment of motor fluctuations in patients with advanced Parkinson’s disease (PD). Its delivery by continuous infusion into the proximal small intestine allows for rapid absorption of levodopa and helps to avoid the fluctuations in levodopa plasma concentrations that occur with oral levodopa therapy. In clinical trials in adults with advanced PD, carbidopa/levodopa ES provided significantly greater improvements in motor fluctuations and troublesome dyskinesia than oral immediate-release carbidopa/levodopa over 12 weeks, and had sustained efficacy in longer-term, open-label studies. Carbidopa/levodopa ES was generally well tolerated in these trials, although complications related to the delivery system were common.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
